Drugs / E75
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00854789 | Dec 2002 → May 2012 | breast cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT00841399 | Jul 2001 → Sep 2012 | breast cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E75 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00854789 ↗ |
| Known as | nelipepimut-S | “BACKGROUND: E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein.” PMID 24907636 ↗ Jun 2014 |
| Modality | Peptide | “E75 is an immunogenic peptide from the HER2/neu protein” PMID 16157940 ↗ Sep 2005 |